These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7138618)

  • 1. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture.
    Ishida T; Tanaka K
    Atherosclerosis; 1982 Aug; 44(2):161-74. PubMed ID: 7138618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis.
    Naito M; Stirk CM; Smith EB; Thompson WD
    Thromb Res; 2000 Apr; 98(2):165-74. PubMed ID: 10713318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fibrinogen degradation products on glomerular mesangial cells in culture.
    Tsumagari T; Tanaka K
    Kidney Int; 1984 Nov; 26(5):712-8. PubMed ID: 6521256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of fibrinogen, fibrin and their degradation products on the behaviour of vascular smooth muscle cells].
    Naito M
    Nihon Ronen Igakkai Zasshi; 2000 Jun; 37(6):458-63. PubMed ID: 10998926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enhanced activation of Glu-plasminogen by urokinase in the presence of fibrin or des A fibrin as measured by the release of B beta peptide and FDP.
    Urano T; Takada Y; Takada A
    Thromb Res; 1984 Dec; 36(5):429-35. PubMed ID: 6084324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of plasminogen by tissue activator is increased specifically in the presence of certain soluble fibrin(ogen) fragments.
    Verheijen JH; Nieuwenhuizen W; Wijngaards G
    Thromb Res; 1982 Aug; 27(4):377-85. PubMed ID: 6890721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen and fibrinolysis in blood and in the arterial wall: its role in advanced atherosclerotic disease.
    Martin-Paredero V; Vadillo J; Diaz J; Espinosa A; Berga C; Segura J; Sanchez J; Barbod A; Villaverde C; Richard CM
    Cardiovasc Surg; 1998 Oct; 6(5):457-62. PubMed ID: 9794264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells.
    Watanabe K; Tanaka K
    Atherosclerosis; 1983 Jul; 48(1):57-70. PubMed ID: 6882509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
    Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
    J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen/fibrin in atherogenesis.
    Smith EB; Thompson WD; Crosbie L; Stirk CM
    Eur J Epidemiol; 1992 May; 8 Suppl 1():83-7. PubMed ID: 1387095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS; Rozenfeld MA; Leonova VB
    Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
    Smith EB; Ashall C
    Atherosclerosis; 1985 May; 55(2):171-86. PubMed ID: 4004989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.
    Ugwu F; Lemmens G; Collen D; Lijnen HR
    Thromb Res; 2001 Apr; 102(1):61-9. PubMed ID: 11323016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin deposition and fibrin degradation products in atherosclerotic plaques.
    Smith EB
    Thromb Res; 1994 Aug; 75(3):329-35. PubMed ID: 7992244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
    Trübestein G; Popov S; Wolf H; Welzel D
    Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Ro 31-8220 on smooth muscle cell proliferation induced by fibrinogen degradation products.
    Zhou B; Zhang JP; Hu ZL; Tao XB; Qian DH
    Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):463-5. PubMed ID: 10322943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biosynthesis of fibrinogen: in vivo studies.
    Bell WR
    Ann N Y Acad Sci; 1983 Jun; 408():503-20. PubMed ID: 6575702
    [No Abstract]   [Full Text] [Related]  

  • 19. T-cell lymphokines, interleukin-4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet-derived growth factor.
    Wang W; Chen HJ; Giedd KN; Schwartz A; Cannon PJ; Rabbani LE
    Circ Res; 1995 Dec; 77(6):1095-106. PubMed ID: 7586221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.